All News Jaguar Health, Inc.

Equities

JAGX

US47010C8055

Market Closed - Nasdaq Other stock markets 01:30:00 28/06/2024 am IST			5-day change	1st Jan Change
3.62 ^USD	-6.22%		-9.05%	-60.15%

30/05	Top Premarket Gainers	MT
29/05	Jaguar Health Expands Out-licensing Agreement With Magdalena Biosciences	MT

All News

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Jaguar Health Regains Compliance with Nasdaq's Bid Price Requirement	27/06	AQ
Jaguar Health : Corporate Presentation – June 21, 2024	22/06	PU
Jaguar Health to Report Pivotal Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer on or Before July 23, 2024	13/06	AQ
Jaguar Health : Private Placement Form 8 K	10/06	PU
Nasdaq Stocks Soaring to the Top with Strategic Splits: NVDA, INBS, JAGX, SINT, GWAV	05/06	AQ
Top Premarket Gainers	30/05	MT
Jaguar Health Expands Out-licensing Agreement With Magdalena Biosciences	29/05	MT
Investigator-Initiated Trial of Jaguar Health's Crofelemer Yields Positive Results for Functional Diarrhea	29/05	AQ
Jaguar Health, Inc. Executes Out- License Deal with Joint Venture Magdalena Biosciences for Botanical Drug Candidate for Schizophrenia	29/05	CI
Jaguar Health, Inc. Announces Results of Third-Party, Investigator-Initiated Study of Crofelemer	28/05	CI
Jaguar Health Announces Reverse Stock Split	20/05	AQ
Jaguar Health Plans 1-for-60 Reverse Split Next Week	18/05	MT
Jaguar Health : Corporate Presentation – May 15, 2024	15/05	PU
Earnings Flash (JAGX) JAGUAR HEALTH Reports Q1 Revenue $2.4M, vs. Street Est of $3M	14/05	MT
Transcript : Jaguar Health, Inc., Q1 2024 Earnings Call, May 14, 2024	14/05
Jaguar Health, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05	CI
Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials and Corporate Updates	09/05	AQ
Jaguar Health Applies for Investigational New Animal Drug Status for Potential Dog Diarrhea Treatment	06/05	MT
Jaguar Health, Inc. Establishes New Investigational New Animal Drug File with the Center for Veterinary Medicine of the U.S. Food and Drug Administration	06/05	CI
Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Pediatric Gastroenterology Conference in Abu Dhabi and Panel Discussion about Microvillus Inclusion Disease	30/04	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Jaguar Health, Inc.

Equities

JAGX

US47010C8055

All News

Filters